These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 2809198)

  • 1. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
    Bodmer S; Strommer K; Frei K; Siepl C; de Tribolet N; Heid I; Fontana A
    J Immunol; 1989 Nov; 143(10):3222-9. PubMed ID: 2809198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression.
    Huber D; Philipp J; Fontana A
    J Immunol; 1992 Jan; 148(1):277-84. PubMed ID: 1727872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.
    Siepl C; Bodmer S; Frei K; MacDonald HR; De Martin R; Hofer E; Fontana A
    Eur J Immunol; 1988 Apr; 18(4):593-600. PubMed ID: 2452745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia.
    Constam DB; Philipp J; Malipiero UV; ten Dijke P; Schachner M; Fontana A
    J Immunol; 1992 Mar; 148(5):1404-10. PubMed ID: 1538124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.
    Zuber P; Kuppner MC; De Tribolet N
    Eur J Immunol; 1988 Oct; 18(10):1623-6. PubMed ID: 3142781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor beta 1.
    Press RD; Misra A; Gillaspy G; Samols D; Goldthwait DA
    Cancer Res; 1989 Jun; 49(11):2914-20. PubMed ID: 2655888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines.
    Cohen PS; Letterio JJ; Gaetano C; Chan J; Matsumoto K; Sporn MB; Thiele CJ
    Cancer Res; 1995 Jun; 55(11):2380-6. PubMed ID: 7757990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of genes from growth factor signaling pathways in glioblastoma cell lines.
    Saxena A; Ali IU
    Oncogene; 1992 Feb; 7(2):243-7. PubMed ID: 1347915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
    Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
    Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
    Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
    Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma.
    Gomella LG; Sargent ER; Wade TP; Anglard P; Linehan WM; Kasid A
    Cancer Res; 1989 Dec; 49(24 Pt 1):6972-5. PubMed ID: 2582439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells.
    Rodeck U; Bossler A; Graeven U; Fox FE; Nowell PC; Knabbe C; Kari C
    Cancer Res; 1994 Jan; 54(2):575-81. PubMed ID: 8275496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers.
    Zou JP; Morford LA; Chougnet C; Dix AR; Brooks AG; Torres N; Shuman JD; Coligan JE; Brooks WH; Roszman TL; Shearer GM
    J Immunol; 1999 Apr; 162(8):4882-92. PubMed ID: 10202033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection?
    Fontana A; Bodmer S; Frei K; Malipiero U; Siepl C
    Ciba Found Symp; 1991; 157():232-8; discussion 238-41. PubMed ID: 1649035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role for transforming growth factor-beta (TGF-beta) in human cancer.
    Gold LI
    Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
    Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
    Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
    Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
    J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.